Novartis atrasentan Phase III data show clinically meaningful proteinuria reduction further advancing company's IgA nephropathy (IgAN) portfolio
May 25, 2024 06:15 ET
|
Novartis Pharma AG
In the ALIGN study, atrasentan, in addition to supportive care with a renin-angiotensin system (RAS) inhibitor, demonstrated a statistically significant 36.1% proteinuria (protein in urine) reduction...
Novartis presents latest Phase III Fabhalta® (iptacopan) data in C3 glomerulopathy (C3G) showing clinically meaningful and statistically significant 35.1% proteinuria reduction vs. placebo
May 25, 2024 06:00 ET
|
Novartis Pharma AG
Secondary endpoint data for estimated glomerular filtration rate (eGFR) showed numerical improvement over 6 months vs. placebo1; additional 6-month open-label data to be presented at a future medical...
Idorsia issues invitation to the 2024 Annual General Meeting of Shareholders
May 23, 2024 01:00 ET
|
Idorsia Pharmaceuticals Ltd
Allschwil, Switzerland – May 23, 2024Idorsia Ltd (SIX: IDIA) today issued the invitation to the upcoming Annual General Meeting (AGM) of Shareholders on behalf of the Board of Directors. The meeting...
Idorsia issues invitation to the 2024 Annual General Meeting of Shareholders
May 23, 2024 01:00 ET
|
Idorsia Pharmaceuticals Ltd
Allschwil, Switzerland – May 23, 2024 Idorsia Ltd (SIX: IDIA) today issued the invitation to the upcoming Annual General Meeting (AGM) of Shareholders on behalf of the Board of Directors. The meeting...
21Shares AG Publication of Base Prospectus
May 22, 2024 11:48 ET
|
21Shares
22 May 2024 The following Base Prospectus has been approved by the Financial Conduct Authority and is available for viewing:Base Prospectus dated 22 May 2024 (the “Base Prospectus”) relating to the...
Kuntarahoitus laskee liikkeeseen 50 miljoonan euron lisäyksen viitelainaan osana joukkovelkakirjalainaohjelmaa
May 22, 2024 03:00 ET
|
Kuntarahoitus Oyj
Kuntarahoitus OyjPörssitiedote22.05.2024 klo 10.00 Kuntarahoitus laskee liikkeeseen 50 miljoonan euron lisäyksen viitelainaan osana joukkovelkakirjalainaohjelmaa Kuntarahoitus Oyj laskee 23.05.2024...
Municipality Finance issues a EUR 50 million tap under its MTN programme
May 22, 2024 03:00 ET
|
Municipality Finance Plc
Municipality Finance PlcStock exchange release 22 May 2024 at 10:00 am (EEST) Municipality Finance issues a EUR 50 million tap under its MTN programme On 23 May 2024 Municipality Finance Plc issues...
Roche granted FDA Breakthrough Device Designation for blood test measuring Lp(a) – a key marker for hereditary cardiovascular risk
May 22, 2024 01:00 ET
|
F. Hoffmann-La Roche Ltd
Approximately one in five people worldwide have elevated Lp(a) levels, putting them at increased risk of cardiovascular diseases including myocardial infarction and stroke.1The Roche Diagnostics...
Sandoz receives European Commission approval for Wyost® and Jubbonti®, the first and only biosimilars of denosumab in Europe
May 22, 2024 01:00 ET
|
Sandoz Group
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE Wyost® (denosumab) and Jubbonti® (denosumab) approved by EC for all...
WISeKey Shares Key Discussion Points From Its FY 2023 Results Conference Call
May 21, 2024 13:43 ET
|
Wisekey International Holding Ltd.
WISeKey Shares Key Discussion Points From Its FY 2023 Results Conference Call Geneva, Switzerland – May 21, 2024: WISeKey International Holding Ltd. (“WISeKey”) (SIX: WIHN, NASDAQ: WKEY), a global...